One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Impact of advanced therapies on surgical recurrence following second ileocolic resection in Crohn’s disease
doi : 10.1093/ecco-jcc/jjaf156
Volume 19, Issue 9, September 2025
Drug repurposing approach for the discovery of therapeutic agents for Crohn’s disease-associated intestinal fibrosis
doi : 10.1093/ecco-jcc/jjaf137
Impact of type 2 diabetes on clinical outcomes and advanced therapy use in patients with Crohn’s disease: a real-world propensity score-matched analysis
doi : 10.1093/ecco-jcc/jjaf157
Day 3 Oxford criteria predict steroid non-response for acute severe ulcerative colitis in the post biologic era
doi : 10.1093/ecco-jcc/jjaf131
Transmural healing in ulcerative colitis patients improves long-term outcomes compared to endoscopic healing alone
doi : 10.1093/ecco-jcc/jjaf149
Assessing intestinal fibrosis using an endoscopic photoacoustic–ultrasound balloon catheter in rabbits and a human subject
doi : 10.1093/ecco-jcc/jjaf155
Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-centre UK study
doi : 10.1093/ecco-jcc/jjaf154
Blood proteomic signatures associated with disease activity in inflammatory bowel diseases
doi : 10.1093/ecco-jcc/jjaf162
Development and validation of a novel patient-reported outcome for microscopic colitis—Microscopic Colitis Score (MCS)
doi : 10.1093/ecco-jcc/jjaf153
A network meta-analysis of capsule endoscopy versus imaging modalities for diagnosing small bowel Crohn’s disease
doi : 10.1093/ecco-jcc/jjaf127
Fecal loss of vedolizumab is associated with ulcerative colitis severity, lower serum vedolizumab levels, and rates of clinical response: results from the FAVOUR study
doi : 10.1093/ecco-jcc/jjaf159
Clinical outcome after entero-enteric anastomosis for Crohn’s disease: a case-control study
doi : 10.1093/ecco-jcc/jjaf163
Anti-tumor necrosis factor treatment from diagnosis is more effective and less costly than conventional “step-up� care for patients with active Crohn’s disease: a cost-effectiveness analysis from the PROFILE trial
doi : 10.1093/ecco-jcc/jjaf150
Real-life durability and risk factors for biologic discontinuation in pediatric inflammatory bowel disease: results from the SIGENP IBD registry
doi : 10.1093/ecco-jcc/jjaf164
Patient-reported outcome measures poorly correlate with objective inflammatory bowel disease activity measures: a systematic review
doi : 10.1093/ecco-jcc/jjaf132
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint
doi : 10.1093/ecco-jcc/jjaf124
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID
doi : 10.1093/ecco-jcc/jjaf166
International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials
doi : 10.1093/ecco-jcc/jjaf170
Unravelling the genetic architecture of inflammatory bowel disease multiplex families with rare and common variant polygenic risk scores
doi : 10.1093/ecco-jcc/jjaf165
Modulating checkpoint molecules in inflammatory bowel diseases as a new therapeutic strategy: a narrative review
doi : 10.1093/ecco-jcc/jjaf160
Combination therapy with biologics and/or small molecules in inflammatory bowel disease: a comprehensive review
doi : 10.1093/ecco-jcc/jjaf161
Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential
doi : 10.1093/ecco-jcc/jjaf167
Scoring indices for assessing endoscopic disease activity in acute severe ulcerative colitis: a systematic review
doi : 10.1093/ecco-jcc/jjaf126
European Crohn’s and Colitis Organisation consensus on dietary management of inflammatory bowel disease
doi : 10.1093/ecco-jcc/jjaf122
Adequacy of disclosures in oral presentations at the 20th Congress of the European Crohn’s and Colitis Organisation
doi : 10.1093/ecco-jcc/jjaf121
Correction to: Spatial immune profiling of Crohn’s disease fistula carcinomas—defining a distinct cancer subtype
doi : 10.1093/ecco-jcc/jjaf171
